[go: up one dir, main page]

Boucher et al., 1990 - Google Patents

Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy

Boucher et al., 1990

Document ID
7910856965817186324
Author
Boucher C
Lange J
Goudsmit J
Mulder J
Tersmette M
de Goede R
Kellam P
Darby G
Larder B
Publication year
Publication venue
The Lancet

External Links

Snippet

Human immunodeficiency type 1 isolates from 18 initially symptom-free men who were treated with zidovudine for 2 years were investigated for drug sensitivity. At the start all the men had persistent core antigenaemia; the acquired immunodeficiency syndrome …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriphage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses

Similar Documents

Publication Publication Date Title
Boucher et al. Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy
Haigwood et al. Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile
Rowland-Jones et al. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant
Tsai et al. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models
Collins et al. Impact of tuberculosis on HIV-1 replication, diversity, and disease progression
Blaak et al. In vitro replication kinetics of human immunodeficiency virus type 1 (HIV-1) variants in relation to virus load in long-term survivors of HIV-1 infection
Goldberg et al. Isolation of a primate type‐C virus from a lymphomatous baboon
Garaci et al. Combination treatment with zidovudine, thymosin α1 and interferon-α in human immunodeficiency virus infectionand interferon-α in human immunodeficiency virus infection
EP2044950B1 (en) Attenuated VIF DNA immunization cassettes for genetic vaccines
Yu et al. Infection with dual-tropic human immunodeficiency virus type 1 variants associated with rapid total T cell decline and disease progression in injection drug users
Bachelez et al. Oligoclonal expansion of HIV-specific cytotoxic CD8 T lymphocytes in the skin of HIV-1-infected patients with cutaneous pseudolymphoma.
KR100388131B1 (en) Clonal cd8 cell lines with antiviral activity and the method isolating them
Saha et al. Evidence of productively infected CD8+ T cells in patients with AIDS: implications for HIV-1 pathogenesis
EP1246647B1 (en) Non-immunosuppressant hiv tat
Jordan et al. COVID-19
Barker CD8+ cell-derived anti-human immunodeficiency virus inhibitory factor
US20040132161A1 (en) Methods and compositions for increasing CD4lymphocyte immune responsiveness
JP2002501367A (en) A novel spumavirus isolated from humans
Sonza et al. Reservoirs for HIV infection and their persistence in the face of undetectable viral load
US20050124645A1 (en) Methods and compositions for increasing CD4lymphocyte immune responsiveness
KR100815888B1 (en) DNA vaccines encoding HIV co-proteins
Tali et al. Respiratory cryptosporidiosis in two patients with HIV infection in a tertiary care hospital in Morocco
US8323928B2 (en) Vaccines and immunotherapeutics derived from the human immunodeficiency virus (HIV) transactivator of transcription protein for the treatment and prevention of HIV disease
US6528308B1 (en) Suppressor of HIV replication and transcription
ES2252971T3 (en) METHOD FOR DETERMINING THE FORECAST OF HIV-INFECTED INDIVIDUALS.